Betterbrand, Kyowa Hakko partner on respiratory health gummy

Betterbrand’s postbiotic immune support formulation expands Betterbrand’s BetterLungs respiratory supplement line.
Hannah Esper
Managing Editor
Hannah Esper profile picture
Betterbrand BetterLungs gummy

Betterbrand and Kyowa Hakko, an international developer of pharmaceuticals and nutraceuticals based in Japan, have partnered to make a first-of-its-kind gummy for respiratory health.

Immunity with Immuse LC-Plasma will be released under Betterbrand's BetterLungs line. The mixed berry flavored gummy includes Immuse, a postbiotic developed by Kyowa Hakko. 

"We base everything we do in science," says Dr. Chris Jackson, Pharm.D, founder and CEO of Betterbrand. "Partnering with an award-winning global ingredient manufacturer like Kyowa increases consumer confidence in both the effectiveness and safety of our health supplements."

Immuse is a patented strain of Lactococcus lactis that stimulates the body's natural defenses by activating plasmacytoid dendritic cells (pDCs). These pDCs activate other immune cells, such as NK, killer-T, helper-T, and B cells, that play crucial roles in regular immune function. Immuse is backed by 27 studies, including 12 clinical trials comprised of 10 efficacy studies and two safety studies. 

"Like everything in the Betterbrand line, this innovative lung support supplement is pharmacist-formulated and packed with natural ingredients backed by science,” said Jason Dorfman, chief business officer at Betterbrand.